

Dear Clients and Partners,

This message as a follow-up to our first two previous weekly message, which you can all consult here: <https://symbioticsgroup.com/covid-19/>

The key elements of the past week are the following:

- **Investor resilience.** Our funds and clients have not encountered any net outflows from investors on any of our 22 active mandates. To the contrary, some are accepting new inflows.
- **Investment operations.** Symbiotics has disbursed 117m\$ year-to-date: 19m\$ in January, 51 m\$ in February and will reach 47m\$ in March. These figures are slightly higher than in previous years. We are reviewing our investment origination situation on a daily basis, but are seeing sustained activity in April in-line with our forecasts, in particular as our aggregate portfolio is expected to grow by 150m\$ in the coming two months.
- **Industry concertation.** Symbiotics has joined several industry concerted efforts and initiatives to make sure everything is done to protect investor interests and keep our markets and industry as stable as possible during confinement periods, in particular with CGAP/World Bank, bilaterally with government agencies, and most importantly amongst key microfinance debt originators. The key word is resilience, ensuring liquidity, renewing and rolling-over maturing loans, in a concerted way to prevent any undue accidents, as the millions of underlying end clients are striving to keep their cash flows afloat.
- **Portfolio performance.** Despite the heightened perceptions of risks, none of them have materialized in any payment default to date. We are nevertheless seeing a number of discussions with MFI CFOs in terms of rescheduling interest or principal repayments, temporarily due to household confinement or economic lockdowns, or increasing credit lines as preventive measures to management their treasury and liquidity situations.
- **Portfolio valuation.** As a result of the above, all outstanding loans have kept an unchanged valuation over the past weeks. We will engage still this week in our valuation exercises for end of March NAVs, as we do every month, reviewing all direct counterparty monitoring and follow-ups. The debt restructuring committee has been preventively reinforced in staffing and meets now twice a week, advising each of our funds on each country and counterparty risk, and establishing whether any provisioning shall be taken in the most troubled cases, based on the most recent information we are receiving day-by-day through our teams and systems.

We trust this comes as useful information for your operations and investor communication. We remain at your disposal for further information, and fully committed and operational in serving your needs and expectations in the best possible way in this extraordinary situation. Please contact your relationship manager with us for fund-specific information.

Yours sincerely,
Symbiotics